Related Experiment Video

Updated: Jan 18, 2026

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.7K

Investigating the Potential of Curcumin in the Treatment of Nonsmall Cell Lung Cancer: A Systematic Review With

Yonglu Guo1, Haohao Xu2, Peng Shen3

  • 1Department of Respiratory and Crical Care Medicine, Shanghai General Hospital Jiuquan Hospital (The People's Hospital of Jiuquan), Jiuquan, China.

Phytotherapy Research : PTR
|September 9, 2025
PubMed

Insights

Curcumin effectively reduces non-small cell lung cancer (NSCLC) tumor volume in animal models. AURKB is identified as a novel high-risk target for NSCLC, offering a scientific basis for curcumin

Area of Science:

  • Pharmacology and Oncology
  • Computational Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide.
  • Curcumin, a natural compound, has demonstrated anti-cancer properties, but its efficacy and precise mechanisms in NSCLC require further elucidation.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of curcumin in non-small cell lung cancer (NSCLC) using meta-analysis.
  • To explore the underlying mechanisms of curcumin's action in NSCLC through network pharmacology, Mendelian randomization, and molecular docking.

Main Methods:

  • Systematic review and meta-analysis of 24 in vivo studies involving 392 animals.
  • Network pharmacology to predict curcumin target genes and identify NSCLC-related genes.
  • Mendelian randomization (MR) and molecular docking to investigate gene-drug interactions and causal relationships.

Main Results:

  • Meta-analysis confirmed curcumin significantly reduces tumor volume in NSCLC animal models (p < 0.001).
  • Network pharmacology identified 229 curcumin target genes and 8 hub genes associated with NSCLC, negatively correlated with immune cell infiltration.
  • Molecular docking showed strong binding affinity between curcumin and the identified hub genes; MR identified AURKB as a high-risk target for NSCLC.

Conclusions:

  • Curcumin demonstrates significant efficacy in reducing NSCLC tumor burden in preclinical models.
  • AURKB is identified as a novel, high-risk target for NSCLC, potentially mediating curcumin's therapeutic effects.
  • This study provides a scientific foundation for the clinical application of curcumin in NSCLC treatment.
Keywords:
curcuminmendelian randomizationmeta‐analysisnetwork pharmacologynonsmall cell lung cancer (NSCLC)systematic review

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K